The Oncode Oncology Bridge Fund*, launched by Oncode BV, is proud to announce the appointment of two Entrepreneurs in Residence (EIR’s). Dr. Markwin Velders (click for bio) brings over 25 years of research experience in the field of tumor immunology and over 18 years of management experience in biotechnology companies. Dr. Allard Kaptein (click for bio) is the Managing Director of Genase Therapeutics. Prior to that, he was co-founder of Acerta Pharma, spinning out the covalent BTK inhibitor series from MSD into Acerta Pharma.

Both EIR’s are seasoned entrepreneurs who have seen companies through from concept to successful exits. They have access to an extensive network of investors and business professionals. In the pre-incorporation phase, they are available for consultation with the research groups to increase their understanding of new enterprise creation realities. Once the Bridge Fund has invested, the EIR’s provide ongoing coaching and mentoring support to portfolio companies.

About the Oncode Oncology Bridge Fund
Oncode BV created the Oncode Oncology Bridge Fund (Bridge Fund) as part of its overall valorization strategy. Its objective is providing early stage capital to support the creation and growth of new enterprises based on excellent science performed by Oncode Researchers and accelerate the translation of innovative cancer research into products and services that benefit patients. The Bridge Fund stands to make a significant impact on the lives of cancer patients. By facilitating the development of new treatment options and diagnostic methods, the Bridge Fund will contribute to improving treatment outcomes for cancer patients all over the world. Please contact Shobhit Dhawan if you’d like to know more about the Bridge Fund.